Literature DB >> 18782052

Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

B Mouillac1, M Manning, T Durroux.   

Abstract

Different series of fluorescent agonists and antagonists have been developed and characterized for arginine-vasopressin and oxytocin G protein-coupled receptors. Both cyclic and linear peptide analogs of the neurohypophysial hormones are useful tools for investigating receptor localization and trafficking, analysing receptor structural organization, and developing new receptor-selective high-throughput ligand screening assays.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18782052      PMCID: PMC2763091          DOI: 10.2174/138955708785740607

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  61 in total

Review 1.  Molecular pharmacology and modeling of vasopressin receptors.

Authors:  M Thibonnier; P Coles; A Thibonnier; M Shoham
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

2.  Structure and expression of a human oxytocin receptor.

Authors:  T Kimura; O Tanizawa; K Mori; M J Brownstein; H Okayama
Journal:  Nature       Date:  1992-04-09       Impact factor: 49.962

3.  Non-peptide oxytocin agonists.

Authors:  Gary R W Pitt; Andrzej R Batt; Robert M Haigh; Andrew M Penson; Peter A Robson; David P Rooker; André L Tartar; Julie E Trim; Christopher M Yea; Michael B Roe
Journal:  Bioorg Med Chem Lett       Date:  2004-09-06       Impact factor: 2.823

4.  The synthesis and biological activity of four novel fluorescent vasopressin analogs.

Authors:  W H Lutz; J M Londowski; R Kumar
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

5.  Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.

Authors:  T Durroux; M Peter; G Turcatti; A Chollet; M N Balestre; C Barberis; R Seyer
Journal:  J Med Chem       Date:  1999-04-08       Impact factor: 7.446

6.  A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists.

Authors:  Stuart R Hawtin; Victoria J Wesley; Rosemary A Parslow; John Simms; Alice Miles; Kim McEwan; Mark Wheatley
Journal:  Mol Endocrinol       Date:  2002-03

7.  Internalization of vasopressin analogs in kidney and smooth muscle cells: evidence for receptor-mediated endocytosis in cells with V2 or V1 receptors.

Authors:  W Lutz; M Sanders; J Salisbury; R Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

8.  Fluorescent peptide hormones: development of high affinity vasopressin analogues.

Authors:  G Guillon; D Barbeau; W Neugebauer; S Guay; L Bilodeau; M N Balestre; N Gallo-Payet; E Escher
Journal:  Peptides       Date:  1992 Jan-Feb       Impact factor: 3.750

9.  Synthesis and biological activities of a fluorescent photoaffinity analog of vasopressin.

Authors:  A Buku; I L Schwartz; D Gazis; C L Ma; P Eggena
Journal:  Endocrinology       Date:  1985-07       Impact factor: 4.736

10.  Design and synthesis of heterofunctional V1a-selective vasopressin receptor ligands with lysine at position 9.

Authors:  J Howl; D C New; M Wheatley
Journal:  J Mol Endocrinol       Date:  1992-10       Impact factor: 5.098

View more
  9 in total

1.  Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

Authors:  Maithé Corbani; Miguel Trueba; Stoytcho Stoev; Brigitte Murat; Julie Mion; Véra Boulay; Gilles Guillon; Maurice Manning
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

2.  Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.

Authors:  Laura Albizu; Martin Cottet; Michaela Kralikova; Stoytcho Stoev; René Seyer; Isabelle Brabet; Thomas Roux; Hervé Bazin; Emmanuel Bourrier; Laurent Lamarque; Christophe Breton; Marie-Laure Rives; Amy Newman; Jonathan Javitch; Eric Trinquet; Maurice Manning; Jean-Philippe Pin; Bernard Mouillac; Thierry Durroux
Journal:  Nat Chem Biol       Date:  2010-07-11       Impact factor: 15.040

Review 3.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

4.  Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.

Authors:  Sylvia Chen; Matthew J Webber; Jean-Pierre Vilardaga; Ashok Khatri; Dennis Brown; Dennis A Ausiello; Herbert Y Lin; Richard Bouley
Journal:  Endocrinology       Date:  2011-08-09       Impact factor: 4.736

5.  Measuring Affinity of Ligands to the Oxytocin Receptor Using Radioligand Binding.

Authors:  Eryn L Werry; Michael Kassiou
Journal:  Methods Mol Biol       Date:  2022

6.  Crystal structure of the human oxytocin receptor.

Authors:  Yann Waltenspühl; Jendrik Schöppe; Janosch Ehrenmann; Lutz Kummer; Andreas Plückthun
Journal:  Sci Adv       Date:  2020-07-15       Impact factor: 14.136

Review 7.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

Review 8.  GPCR oligomers in pharmacology and signaling.

Authors:  Javier González-Maeso
Journal:  Mol Brain       Date:  2011-05-27       Impact factor: 4.041

9.  Directed evolution for high functional production and stability of a challenging G protein-coupled receptor.

Authors:  Yann Waltenspühl; Jeliazko R Jeliazkov; Lutz Kummer; Andreas Plückthun
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.